SMMT
Summit Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$17.85
+0.73%Sep 15, 2026, 10:00 UTC
Summit Therapeutics presented updated overall survival results from the global Phase III HARMONi clinical trial of ivonescimab plus chemotherapy in Western and Asian patients at WCLC 2026 in Seoul, Republic of Korea.
Source:Sep 4, 2026, 15:53 UTC
Summit Therapeutics stock jumped 17% after ivonescimab showed a significant overall survival benefit over Keytruda in a China phase III lung cancer study.
Source:Sep 2, 2026, 21:41 UTC
Akeso Inc. announced positive overall survival results from the Phase III HARMONi-2 study, showing ivonescimab monotherapy significantly improved OS versus pembrolizumab in PD-L1-positive advanced NSCLC.
Aug 25, 2026, 22:00 UTC
Akeso Inc. announced positive topline results from the Phase III HARMONi-GI1 study of ivonescimab plus chemotherapy in advanced biliary tract cancer, showing statistically significant overall survival benefit versus durvalumab plus chemotherapy.
Aug 25, 2026, 16:33 UTC
Summit Therapeutics announced that The Lancet Oncology published primary analysis results from its global Phase 3 HARMONi trial, showing that its drug ivonescimab combined with chemotherapy extends progression-free survival in lung cancer patients.
Source:Aug 5, 2026, 12:28 UTC
On August 5, 2026, Akeso announced that its overseas partner Summit Therapeutics will initiate a global Phase II/III clinical study (HARMONi-GU1/AK112-3008) combining ivonescimab with enfortumab vedotin for first-line treatment of locally advanced or metastatic urothelial carcinoma, with Akeso leading the China portion and Summit leading overseas portions.
Source:Jul 31, 2026, 17:22 UTC
The FDA is reviewing Summit Therapeutics' Biologics License Application for ivonescimab, with a decision expected by November 14, 2026.
Source:Jul 24, 2026, 15:53 UTC
Summit Therapeutics raised $230.8 million in gross proceeds through its ATM facility in Q2 2026 and an additional $68.4 million after the quarter.
Source:Jul 24, 2026, 02:40 UTC
Summit Therapeutics Inc. held its Q2 2026 earnings call.
Source:Jul 22, 2026, 20:30 UTC
Arcus Biosciences and Summit Therapeutics entered into a clinical trial collaboration to evaluate casdatifan combined with ivonescimab in kidney cancer.
Source:Jul 22, 2026, 11:56 UTC
Summit Therapeutics released updated overall survival results from its Phase III HARMONi clinical trial evaluating ivonescimab plus chemotherapy for non-small cell lung cancer.
Jul 14, 2026, 11:00 UTC
Summit Therapeutics signed an agreement to sell its Phase III asset ridinilazole to Biossil, Inc.
Source:Jun 11, 2026, 00:00 UTC
Summit Therapeutics canceled its planned $500 million secondary share offering one day after announcing it, citing market conditions.
Source:May 31, 2026, 12:00 UTC
Akeso and Summit Therapeutics presented positive Phase 3 trial results for their experimental lung cancer drug ivonescimab at the American Society of Clinical Oncology annual meeting.